Grufity logoGrufity logo

AtriCure Inc Stock Research

ATRC

39.35USD+0.21(+0.54%)Delayed

Market Summary

USD39.35+0.21
Delayed
0.54%

ATRC Alerts

ATRC Stock Price

ATRC RSI Chart

ATRC Valuation

Market Cap

1.8B

Price/Earnings (Trailing)

-39.43

Price/Sales (Trailing)

5.55

EV/EBITDA

-53.51

Price/Free Cashflow

-46.95

ATRC Price/Sales (Trailing)

ATRC Profitability

Operating Margin

74.44%

EBT Margin

-13.98%

Return on Equity

-10.17%

Return on Assets

-7.94%

Free Cashflow Yield

-2.13%

ATRC Fundamentals

ATRC Revenue

Revenue (TTM)

330.4M

Revenue Y/Y

20.23%

Revenue Q/Q

5.74%

ATRC Earnings

Earnings (TTM)

-46.5M

Earnings Y/Y

69.65%

Earnings Q/Q

66.02%

Price Action

52 Week Range

32.5168.58
(Low)(High)

Last 7 days

3%

Last 30 days

-9.2%

Last 90 days

-7.8%

Trailing 12 Months

-33.7%

ATRC Financial Health

Current Ratio

3.69

ATRC Investor Care

Shares Dilution (1Y)

1.19%

Diluted EPS (TTM)

-1.02

Peers (Alternatives to AtriCure)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
104.1B
18.4B
2.26% 8.00%
44.16
5.64
7.84% 18.25%
84.2B
6.2B
-4.47% -13.27%
63.66
13.53
8.97% -22.43%
69.1B
12.7B
0.59% 12.45%
99.06
5.45
6.68% -32.95%
67.4B
19.0B
-5.16% -6.78%
41.86
3.55
-0.43% -8.78%
49.8B
5.4B
2.41% -25.12%
32.74
9.26
2.86% 1.25%
MID-CAP
7.2T
489.7M
9.34% 31.15%
82.2K
16.8K
106.51% 2464.23%
10.2B
847.1M
-3.64% 34.52%
-5.1K
12.05
13.32% -137.89%
5.2B
1.0B
-11.64% -20.31%
30.19
5.09
6.76% 24.45%
3.5B
410.9M
4.51% -3.13%
-29.82
8.43
27.29% -14.60%
2.7B
801.2M
1.13% -58.87%
-28.25
3.34
14.00% -707.69%
SMALL-CAP
1.7B
138.6M
-15.68% 29.18%
-30.43
12.07
36.62% -10.44%
1.6B
350.9M
10.38% 49.06%
-10.84
4.7
44.26% -5.42%
1.3B
820.0M
-8.35% -12.22%
25.89
1.59
10.13% 701.59%
828.4M
239.8M
0.30% 1.49%
-21.88
3.45
-4.74% -31.15%

Financials for AtriCure

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue4.7%330316303290274
Cost Of Revenue5.9%84.0080.0076.0073.0068.00
Gross Profit4.3%246236226217206
Operating Expenses0.6%289287168160151
  S&GA Expenses0.8%231229222217205
  R&D Expenses-0.1%57.0057.0054.0051.0049.00
EBITDA23.9%-33.15-43.5966.0064.00-
EBITDA Margin27.3%-0.10*-0.14*0.22*0.22*-
Earnings Before Taxes17.3%-46.20-55.8454.0052.0050.00
EBT Margin21.0%-0.14*-0.18*0.18*0.18*-
Interest Expenses10.6%5.005.005.005.005.00
Net Income17.1%-46.47-56.0453.0052.0050.00
Net Income Margin20.8%-0.14*-0.18*0.18*0.18*-
Free Cahsflow-4.6%-39.02-37.31-32.11-40.90-
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets0.6%585582587585615
  Current Assets1.4%215212206200196
    Cash Equivalents19.0%58.0049.0055.0028.0044.00
  Inventory4.5%46.0044.0041.0041.0039.00
  Net PPE6.9%39.0036.0033.0031.00-
  Goodwill0%235235235235235
Liabilities-2.2%129132131122132
  Current Liabilities1.4%58.0058.0056.0047.0056.00
    LT Debt, Non Current-5.4%57.0060.0060.0060.0060.00
Shareholder's Equity1.4%457450457463484
  Retained Earnings-1.3%-326-322-310-295-280
  Additional Paid-In Capital1.2%787778771762765
Shares Outstanding0.3%47.0046.0046.0046.0046.00
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations-1.2%-22.14-21.89-20.33-29.10-13.78
  Share Based Compensation-1.2%29.0029.0029.0029.0028.00
Cashflow From Investing15.6%44.0038.0016.00-20.3624.00
Cashflow From Financing-8.0%-7.06-6.53-8.39-7.43-7.64

Risks for ATRC

What is the probability of a big loss on ATRC?

90%


Probability that AtriCure stock will be more than 20% underwater in next one year

56.1%


Probability that AtriCure stock will be more than 30% underwater in next one year.

36.1%


Probability that AtriCure stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ATRC drawdown profile look like?

Y-axis is the maximum loss one would have experienced if AtriCure was unfortunately bought at previous high price.

Drawdowns

Returns for ATRC

Cumulative Returns on ATRC

16.3%


10-Year Cumulative Returns

12.3%


7-Year Cumulative Returns

13.2%


5-Year Cumulative Returns

8.8%


3-Year Cumulative Returns

What are the long-term rolling returns for ATRC?

FIve years rolling returns for AtriCure.

Annualized Returns

Which funds bought or sold ATRC recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
added
91.15
299,217
554,217
-%
2023-03-06
Rockefeller Capital Management L.P.
added
15.01
25,000
108,000
-%
2023-02-28
Voya Investment Management LLC
reduced
-79.31
-2,525,950
775,052
-%
2023-02-24
SRS Capital Advisors, Inc.
unchanged
-
21.00
1,021
-%
2023-02-21
MACQUARIE GROUP LTD
added
1.00
7,768,000
61,065,000
0.07%
2023-02-17
TRUIST FINANCIAL CORP
reduced
-22.51
-126,372
914,628
-%
2023-02-16
CHARTWELL INVESTMENT PARTNERS, LLC
added
6.05
154,000
913,000
0.04%
2023-02-15
JANE STREET GROUP, LLC
added
13.11
140,741
637,741
-%
2023-02-15
MBM Wealth Consultants, LLC
new
-
3,000
3,000
-%
2023-02-15
Steward Partners Investment Advisory, LLC
sold off
-100
-1,000
-
-%

1–10 of 48

Latest Funds Activity

Are funds buying ATRC calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own ATRC
No. of Funds

AtriCure News

Benzinga

AtriCure Board Member Awarded $393K Worth of Stock Options - AtriCure (NASDAQ:ATRC).

Benzinga,
28 hours ago

Yahoo Finance

Yahoo Finance

Penny Stocks

Schedule 13G FIlings of AtriCure

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
alliancebernstein l.p.
7.7%
3,565,726
SC 13G/A
Feb 14, 2023
alger associates inc
3.8%
1,755,398
SC 13G/A
Feb 09, 2023
vanguard group inc
9.44%
4,389,815
SC 13G/A
Feb 03, 2023
blackrock inc.
8.0%
3,735,766
SC 13G/A
Feb 03, 2023
invesco ltd.
7.2%
3,367,324
SC 13G/A
Feb 14, 2022
price t rowe associates inc /md/
4.2%
1,945,751
SC 13G/A
Feb 14, 2022
alliancebernstein l.p.
7.5%
3,455,856
SC 13G
Feb 14, 2022
alger associates inc
7.1%
3,240,847
SC 13G/A
Feb 09, 2022
vanguard group inc
9.22%
4,234,298
SC 13G/A
Feb 09, 2022
invesco ltd.
5.3%
2,437,617
SC 13G/A

ATRC Fair Value

AtriCure fair value in different scenarios

The table shows the Fair Value estimates for AtriCure for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

6.08

-84.55%

7.25

-81.58%

9.10

-76.87%

10.74

-72.71%

12.13

-69.17%
Current Inflation

5.77

-85.34%

6.78

-82.77%

8.34

-78.81%

9.71

-75.32%

10.87

-72.38%
Very High Inflation

5.39

-86.30%

6.21

-84.22%

7.43

-81.12%

8.51

-78.37%

9.42

-76.06%

Historical AtriCure Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of AtriCure

View All Filings
Date Filed Form Type Document
Mar 15, 2023
4
Insider Trading
Mar 03, 2023
4
Insider Trading
Mar 03, 2023
4
Insider Trading
Mar 03, 2023
4
Insider Trading
Mar 03, 2023
4
Insider Trading
Mar 03, 2023
4
Insider Trading
Mar 03, 2023
4
Insider Trading
Mar 03, 2023
4
Insider Trading
Mar 03, 2023
4
Insider Trading
Mar 01, 2023
4
Insider Trading

Latest Insider Trading transactions for ATRC

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-13
Collar Mark A
acquired
93,000
9.3
10,000
-
2023-03-01
Privitera Salvatore
acquired
-
-
24,140
chief technical officer
2023-03-01
Yount Deborah Lee
acquired
-
-
12,239
chief human resources officer
2023-03-01
Wirick Angela L
sold (taxes)
-137,077
38.81
-3,532
chief financial officer
2023-03-01
Noznesky Justin J
sold (taxes)
-274,891
38.81
-7,083
chief mktg & strategy officer
2023-03-01
Seith Douglas J
acquired
-
-
42,507
chief operating officer
2023-03-01
Wirick Angela L
acquired
-
-
24,478
chief financial officer
2023-03-01
Seith Douglas J
sold (taxes)
-453,572
38.81
-11,687
chief operating officer
2023-03-01
Doraiswamy Vinayak
acquired
-
-
24,140
chief scientific officer
2023-03-01
Dahlquist Karl S.
sold (taxes)
-267,556
38.81
-6,894
chief legal officer

1–10 of 50

Michael H. Carrel
880
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

ATRC Income Statement

2022-12-31
Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Income Statement [Abstract]   
Revenue$ 330,379$ 274,329$ 206,531
Cost of revenue84,43968,46957,222
Gross profit245,940205,860149,309
Operating expenses (benefit):   
Research and development expenses57,33748,50643,070
Selling, general and administrative expenses231,272204,649150,829
Change in fair value of contingent consideration (Note 2)0(184,800)(357)
Intangible asset impairment (Note 4)082,3000
Total operating expenses288,609150,655193,542
(Loss) income from operations(42,669)55,205(44,233)
Other income (expense):   
Interest expense(4,986)(4,918)(4,885)
Interest income1,9944661,101
Other(537)(366)(24)
(Loss) income before income tax expense(46,198)50,387(48,041)
Income tax expense268188114
Net (loss) income$ (46,466)$ 50,199$ (48,155)
Basic net (loss) income per share (in usd per share)$ (1.02)$ 1.11$ (1.14)
Diluted net (loss) income per share (in usd per share)$ (1.02)$ 1.09$ (1.14)
Weighted average shares outstanding, basic (in shares)45,74045,06642,125
Weighted average shares outstanding, diluted (in shares)45,74046,03942,125
Comprehensive (loss) income:   
Unrealized loss on investments$ (2,811)$ (941)$ (46)
Foreign currency translation adjustment(337)(319)516
Other comprehensive (loss) income(3,148)(1,260)470
Net (loss) income(46,466)50,199(48,155)
Comprehensive (loss) income, net of tax$ (49,614)$ 48,939$ (47,685)

ATRC Balance Sheet

2022-12-31
Consolidated Balance Sheets - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 58,099,000$ 43,654,000
Short-term investments63,014,00075,436,000
Accounts receivable, less allowance for credit losses of $230 and $1,09642,693,00033,021,000
Inventories45,931,00038,964,000
Prepaid and other current assets5,477,0005,001,000
Total current assets215,214,000196,076,000
Assets, Noncurrent  
Long-term investments51,509,000104,338,000
Property and equipment, net38,833,00031,409,000
Operating lease right-of-use assets3,787,0004,761,000
Intangible assets, net39,339,00042,992,000
Goodwill234,781,000234,781,000
Other noncurrent assets1,985,000955,000
Total Assets585,448,000615,312,000
Current liabilities:  
Accounts payable19,898,00018,597,000
Accrued liabilities33,022,00036,092,000
Other current liabilities and current maturities of debt and leases5,472,0001,756,000
Total current liabilities58,392,00056,445,000
Long-term debt56,834,00059,741,000
Finance lease liabilities9,147,00010,082,000
Operating lease liabilities3,095,0004,068,000
Other noncurrent liabilities1,226,0001,220,000
Total Liabilities128,694,000131,556,000
Commitments and contingencies (Note 10)
Stockholders’ Equity:  
Common stock, $0.001 par value, 90,000 shares authorized; 46,563 and 46,016 issued and outstanding47,00046,000
Additional paid-in capital787,422,000764,811,000
Accumulated other comprehensive loss(4,096,000)(948,000)
Accumulated deficit(326,619,000)(280,153,000)
Total Stockholders’ Equity456,754,000483,756,000
Total Liabilities and Stockholders’ Equity$ 585,448,000$ 615,312,000